Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects

NCT04987229 · clinicaltrials.gov ↗

PHASE3

Phase

ENROLLING_BY_INVITATION

Status

236

Enrollment

INDUSTRY

Sponsor class

Conditions

Bipolar I Disorder
Schizophrenia

Interventions

DRUG: OLZ/SAM

Sponsor

Alkermes, Inc.